JOURNAL of
ONCOLOGICAL
SCIENCES

LETTER TO THE EDITOR

Distribution Data of Epidermal Growth Factor Receptor Mutations Detected by Next-Generation Sequencing Method in Non-Small Cell Lung Cancer
Received Date : 11 May 2021
Accepted Date : 08 Jun 2021
Available Online : 18 Jun 2021
Doi: 10.37047/jos.2021-84407 - Article's Language: EN
J Oncol Sci. 2021;7(2):77-80
This is an open access article under the CC BY-NC-ND license
KAYNAKLAR
  1. World Health Organization. Cancer. 2020. Available from: [Link]  Accessed 15 Feb 2021
  2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, [Link]  Accessed 12 Feb 2021
  3. Kara F, Keskinkılıç B. Türkiye Kanser İstatistikleri 2016. Halk Sağlığı Genel Müdürlüğü, Sağlık Bakanlığı. Ankara: 2019. [Link] 
  4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013; 339 (6127):1546-1558. [Crossref]  [PubMed]  [PMC] 
  5. Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 2013;13(3):394-401. [Crossref]  [PubMed] 
  6. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323-358. [Crossref]  [PubMed] 
  7. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947-955. [Crossref]  [PubMed] 
  8. Riess JW, Gandara D. Lung cancer. In: Hensley ML, ed. ASCO-SEP Medical Oncology Self-Evaluation Program. 6th ed. Alexandria: American Society of Clinical Oncology, cop.; 2018:532-639.
  9. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-346. [Crossref]  [PubMed] 
  10. Barlesi F, Mazieres J, Merlio JP, et al; Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-1426. [Crossref]  [PubMed] 
  11. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. [Crossref]  [PubMed] 
  12. Al-Kuraya K, Siraj AK, Bavi P, et al. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol. 2006;37(4):453-457. [Crossref]  [PubMed] 
  13. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12(24):7232-7241. [Crossref]  [PubMed] 
  14. O'Kane GM, Bradbury PA, Feld R, et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. July 2017;109:137-144. [Crossref]  [PubMed] 
  15. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Non-small cell lung cancer, version 6.2020. June 15, 2020.
  16. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16):5267-5273. [Crossref]  [PubMed]  [PMC]